Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) was upgraded by analysts at Rosenblatt Securities to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.
A number of other analysts have also weighed in on GLX. Benchmark upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Monday, March 31st. Cantor Fitzgerald upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, February 25th. Finally, BTIG Research upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Monday, April 14th. Five equities research analysts have rated the stock with a strong buy rating, According to MarketBeat, the stock currently has an average rating of “Strong Buy”.
View Our Latest Stock Analysis on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Price Performance
Featured Articles
- Five stocks we like better than Bradmer Pharmaceuticals
- Investing In Automotive Stocks
- 3 Hot Trades for Insiders, But Are They Good Buys for Investors?
- How to start investing in penny stocks
- Why Qualcomm’s Latest Price Target Can’t Be Ignored
- Differences Between Momentum Investing and Long Term Investing
- Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
